ArticleJournal of neuro-oncology1999
Efficacy of proton magnetic resonance spectroscopy in clinical decision making for patients with suspected malignant brain tumors.
Article in Journal of neuro-oncology, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 78 citations in OpenAlex.
- A systematic literature review of magnetic resonance spectroscopy for the characterization of brain tumors.AJNR. American journal of neuroradiology · 2006Pooled it
- Metabolic response of glioblastoma to superselective intra-arterial cerebral infusion of bevacizumab: a proton MR spectroscopic imaging study.AJNR. American journal of neuroradiology · 2012Trial
- Characterization of intracranial space-occupying lesions by ⁹⁹(m)Tc-Tetrofosmin SPECT.Journal of neuro-oncology · 2011Trial
- The Utility of Spectroscopic MRI in Stereotactic Biopsy and Radiotherapy Guidance in Newly Diagnosed Glioblastoma.Tomography (Ann Arbor, Mich.) · 2024Article
- Diagnostic accuracy and added value of qualitative radiological review ofNeuro-oncology practice · 2019Article
- Evaluation of the added value ofNeuro-oncology practice · 2018Article
- The value of magnetic resonance spectroscopy as a supplement to MRI of the brain in a clinical setting.PloS one · 2018Article
- Creatine CEST MRI for Differentiating Gliomas with Different Degrees of Aggressiveness.Molecular imaging and biology · 2017Article
- Combined MRI and MRS improves pre-therapeutic diagnoses of pediatric brain tumors over MRI alone.Neuroradiology · 2015Article
- CEST signal at 2ppm (CEST@2ppm) from Z-spectral fitting correlates with creatine distribution in brain tumor.NMR in biomedicine · 2015Article
- Spatial characteristics of newly diagnosed grade 3 glioma assessed by magnetic resonance metabolic and diffusion tensor imaging.Translational oncology · 2012Article
- Use of in vivo two-dimensional MR spectroscopy to compare the biochemistry of the human brain to that of glioblastoma.Radiology · 2011Article
- MR spectroscopy in radiation injury.AJNR. American journal of neuroradiology · 2009Review
- Proton MR spectroscopy improves discrimination between tumor and pseudotumoral lesion in solid brain masses.AJNR. American journal of neuroradiology · 2009Article
- The use of short-echo-time 1H MRS for childhood cerebellar tumours prior to histopathological diagnosis.Pediatric radiology · 2007Article
- Efficacy of proton magnetic resonance spectroscopy in neurological diagnosis and neurotherapeutic decision making.NeuroRx : the journal of the American Society for Experimental NeuroTherapeutics · 2005Review
- MR spectroscopy in the evaluation of recurrent contrast-enhancing lesions in the posterior fossa after tumor treatment.Neuroradiology · 2004Article
- Preoperative proton-MR spectroscopy of gliomas--correlation with quantitative nuclear morphology in surgical specimen.Journal of neuro-oncology · 2003Article
- Imaging changes after stereotactic radiosurgery of primary and secondary malignant brain tumors.Journal of neuro-oncology · 2002Article
- Proton MR spectroscopic evaluation of suspicious brain lesions after stereotactic radiotherapy.AJNR. American journal of neuroradiology · 2001Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We wished to determine the utility of single voxel proton (1H) magnetic resonance spectroscopy (MRS) when used as an alternative or adjunct to brain biopsy in patients harboring lesions suggestive of brain tumors identified by MRI scan. Fifteen patients (age 7-58 years) with MRI scans and clinical histories suggestive of primary brain tumors underwent single voxel 1H-MRS. MRS (16 regions of interest in 15 patients) was used to aid in differentiation between tumor and other pathologies such as stroke or demyelinating plaque (n = 6), radiation necrosis (n = 5), or edema (n = 5). Spectra were quantified to determine absolute molar values of N-acetyl aspartate (NAA), choline (Cho), creatine (Cr), lactate (LAC), and myo-inositol (mI), metabolite ratios relative to Cr were calculated, and spectra were interpreted based on metabolite ratios. Subsequent clinical management was based on MRS interpretation, and patients were then followed to determine if MRS interpretation accurately predicted clinical outcome or surgical findings. Mean follow-up was 12.5 months (range 3-28 months). MRS suggested the presence of recurrent tumor in 7 cases, all of which were subsequently 'confirmed' by tumor resection (n = 4) or disease progression (n = 3). MRS suggested the presence of new tumor in 1 case, subsequently confirmed by surgical resection. MRS suggested the presence of necrosis in 3 patients; all 3 remained radiographically stable during the follow-up period, and one was confirmed by stereotactic biopsy. MRS suggested non-neoplastic lesions in 4 cases, 3 of whom were followed until radiographic resolution of lesions and one of which was confirmed as a pyogenic abscess via stereotactic aspiration. Overall, MRS accurately predicted the pathological nature and clinical outcome of lesions in 15/16 (96%) situations, influenced clinical decision making in 12 cases, and altered surgery planning in 7 patients. In appropriate circumstances MRS can reduce the need for biopsy, and provide an important guide for clinical decision-making in difficult cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.